# US 2023/0400468 A1 · Human IgG autoantibodies against galactose-deficient IgA1, preparation method thereof, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0400468 A1
- Document ID: US20230400468A1
- Status: Published application
- Kind: A1
- Application number: 18/180,745
- Filed: 2023-03-08
- Published: 2023-12-14
- Earliest claimed: 2022-06-08
- Assignees: National Defense Medical Center
- Applicants: National Defense Medical Center
- Inventors: Shuk-Man KA; Chia-Chao Wu; Ann CHEN
- Web page: https://patentgrep.com/patent/US20230400468A1

## CPC

- G01N 33/577: involving monoclonal antibodies {binding reaction mechanisms characterised by the use of monoclonal antibodies (G01N33/5302 - G01N33/576 take precedence)}
- G01N 33/6854: {Immunoglobulins}
- G01N 2800/347: Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The current invention provides high specificity monoclonal antibodies, which can specifically bind to Gd-IgA as a novel non-invasive method for rapid diagnosing of IgAN subjects, which can be applied to unravel the mechanisms of IgA nephropathy and establish therapeutical strategies.

## Claims

### Claim 1

A reagent set for detecting the mechanism of IgA nephropathy and establishing a treatment strategy, which comprises an IgG monoclonal antibody.

### Claim 2 (depends on 1)

A reagent set according to claim 1, wherein the IgG monoclonal antibody is selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12.

### Claim 3

A method for detecting galactose-deficient O-glycosyl IgA1, comprising:
(a) obtaining a biological sample from a subject; and
(b) using an IgG monoclonal antibody in an immunoassay to detect galactose deficient O-glycosyl IgA1 in the subject.

### Claim 4 (depends on 3)

A method according to claim 3, wherein the subject is selected from the group consisting of IgA nephropathy (IgAN) subjects, lupus nephritis (LN) subjects and healthy subjects.

### Claim 5 (depends on 3)

A method according to claim 3, wherein the biological sample is plasma, serum or blood.

### Claim 6 (depends on 3)

A method according to claim 3, wherein the IgG monoclonal antibody is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.

### Claim 7 (depends on 3)

A method according to claim 3, wherein the galactose-deficient O-glycosyl is selected from T225, T228, T230, T232, T233, T236, and All-HR-C.

### Claim 8

A method for diagnosing a subject with IgA nephropathy (IgAN), comprising:
(a) using an IgG monoclonal antibody in an immunoassay; and
(b) determining whether the antibody binds to galactose-deficient O-glycosyl of IgA1, the binding of the antibody to galactose-deficient O-glycosyl of IgA1 indicating that the subject has or is at risk of developing IgA nephropathy.

### Claim 9 (depends on 8)

A method according to claim 8, wherein the IgG monoclonal antibody is selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12.

### Claim 10 (depends on 8)

A method according to claim 8, wherein the galactose-deficient O-glycosyl is selected from T225, T228, T230, T232, T233, T236, and All-HR-C.
